{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:40:25Z","timestamp":1792456825052,"version":"4.5.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Provention Bio"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background &amp; Aims<\/jats:title>\n                    <jats:p>PRV-300 is a fully human IgG4\u03ba monoclonal antibody that binds the extracellular domain of human toll-like receptor 3, which is overexpressed in the inflamed colonic epithelium in patients with inflammatory bowel disease. This study aimed at proving its safety and efficacy in patients with ulcerative colitis (UC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with moderate-to-severe UC (Mayo Clinical Score [MCS] 6-12) were randomized to receive 7 doses of PRV-300 intravenously or matched placebo (PBO). After a 12-week treatment period, participants underwent an 8-week follow-up. The primary endpoint was to assess the safety and tolerability of PRV-300. Secondary endpoints included assessment of pharmacodynamics, pharmacokinetics, immunogenicity, and endoscopic disease activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 38 patients were randomized (28 in PRV-300 arm, 9 in placebo arm), of whom 32 completed the trial (24 and 8, respectively). Although TEAEs and TE-SAEs were numerically higher with PRV-300 than placebo (50.0% vs 11.1% and 39.3% vs 0.0%, respectively), the drug was well-tolerated, with only 7.1% (2\/28) discontinuing therapy due to AEs and most events being mild, non-specific, or related to underlying disease. In colonic biopsies, PRV-300 had a greater, albeit not statistically significant, effect on the downregulation of TLR3 expression, but not on a UC gene expression signature. No differences in MCS and endoscopic severity were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While PRV-300 demonstrated an acceptable safety profile, TLR3 blockade did not translate into clinical benefit despite exploratory evidence of target engagement. Our results are challenging a pivotal role of the mode-of-action for the pathogenesis of UC (funded by Provention Bio)<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration number<\/jats:title>\n                    <jats:p>ClinicalTrials.gov (NCT03849599).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjag154","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:02:04Z","timestamp":1792454524000},"source":"Crossref","is-referenced-by-count":0,"title":["Safety and tolerability of anti-toll-like receptor 3, monoclonal antibody PRV-300 in patients with moderate-to-severe ulcerative colitis: a randomized phase 1B clinical trial (PULSE)"],"prefix":"10.1093","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7331-587X","authenticated-orcid":false,"given":"Jagoda","family":"Pokryszka","sequence":"first","affiliation":[{"name":"Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna , Vienna,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail M","family":"Comer","sequence":"additional","affiliation":[{"name":"Provention Bio, Red Bank , NJ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla A","family":"Richmond","sequence":"additional","affiliation":[{"name":"Johnson & Johnson Innovative Medicine, Horsham , PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Leon","sequence":"additional","affiliation":[{"name":"Provention Bio, Red Bank , NJ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2088-091X","authenticated-orcid":false,"given":"Walter","family":"Reinisch","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna , Vienna,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"key":"2026101920015609700_jjag154-B1","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1186\/s12876-021-02028-5","article-title":"The LUCID study: living with ulcerative colitis; identifying the socioeconomic burden in Europe","volume":"21","author":"Ruiz-Casas","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"2026101920015609700_jjag154-B2","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"2026101920015609700_jjag154-B3","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/ecco-jcc\/jjy149","article-title":"Deep remission with vedolizumab in patients with moderately to severely active ulcerative colitis: a GEMINI 1 post hoc analysis","volume":"13","author":"Sandborn","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2026101920015609700_jjag154-B4","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1111\/apt.14030","article-title":"Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn\u2019s disease and ulcerative colitis controlled trials","volume":"45","author":"Cholapranee","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2026101920015609700_jjag154-B5","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/cei.12136","article-title":"Expression of toll-like receptor-3 is enhanced in active inflammatory bowel disease and mediates the excessive release of lipocalin 2","volume":"173","author":"\u00d8stvik","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"2026101920015609700_jjag154-B6","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1097\/mib.0000000000000035","article-title":"Mucosal toll-like receptor 3-dependent synthesis of complement factor B and systemic complement activation in inflammatory bowel disease","volume":"20","author":"Ostvik","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2026101920015609700_jjag154-B7","doi-asserted-by":"publisher","DOI":"10.3390\/cells10061374","article-title":"Toll-like receptor signaling in the establishment and function of the immune system","volume":"10","author":"Aluri","year":"2021","journal-title":"Cells"},{"key":"2026101920015609700_jjag154-B8","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/s1097-2765(02)00708-6","article-title":"The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition","volume":"10","author":"Goetz","year":"2002","journal-title":"Mol Cell"},{"key":"2026101920015609700_jjag154-B9","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1440-1746.2005.03977.x","article-title":"Rotavirus double-stranded RNA induces apoptosis and diminishes wound repair in rat intestinal epithelial cells","volume":"21","author":"Sato","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"2026101920015609700_jjag154-B10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/infdis\/jit432","article-title":"Poly(I: C)-induced protection of neonatal mice against intestinal Cryptosporidium parvum infection requires an additional TLR5 signal provided by the gut flora","volume":"209","author":"Lantier","year":"2014","journal-title":"J Infect Dis"},{"key":"2026101920015609700_jjag154-B11","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.immuni.2013.02.024","article-title":"Double-stranded RNA of intestinal commensal but not pathogenic bacteria triggers production of protective interferon-\u03b2","volume":"38","author":"Kawashima","year":"2013","journal-title":"Immunity"},{"key":"2026101920015609700_jjag154-B12","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"2026101920015609700_jjag154-B13","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1159\/000499870","article-title":"Relationship between serum adalimumab levels and clinical outcome in the treatment of inflammatory bowel disease","volume":"37","author":"Hinojosa","year":"2019","journal-title":"Dig Dis"},{"key":"2026101920015609700_jjag154-B14","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1093\/ecco-jcc\/jjz071","article-title":"Low golimumab trough levels at week 6 are associated with poor clinical, endoscopic and histological outcomes in ulcerative colitis patients: pharmacokinetic and pharmacodynamic sub-analysis of the evolution study","volume":"13","author":"Magro","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2026101920015609700_jjag154-B15","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.cgh.2017.11.050","article-title":"Association of vedolizumab level, anti-drug antibodies, and \u03b14\u03b27 occupancy with response in patients with inflammatory bowel diseases","volume":"16","author":"Ungar","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026101920015609700_jjag154-B16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.clim.2013.10.012","article-title":"Toll-like receptor 3 differently modulates inflammation in progressive or benign multiple sclerosis","volume":"150","author":"Saresella","year":"2014","journal-title":"Clin Immunol"},{"key":"2026101920015609700_jjag154-B17","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1093\/cvr\/cvt033","article-title":"Toll-like receptor 3 and 4 signalling through the TRIF and TRAM adaptors in haematopoietic cells promotes atherosclerosis","volume":"99","author":"Lundberg","year":"2013","journal-title":"Cardiovasc Res"},{"key":"2026101920015609700_jjag154-B18","doi-asserted-by":"publisher","first-page":"e32110","DOI":"10.1371\/journal.pone.0032110","article-title":"Intranasal administration of poly(I: C) and LPS in BALB\/c mice induces airway hyperresponsiveness and inflammation via different pathways","volume":"7","author":"Starkhammar","year":"2012","journal-title":"PLoS One"},{"key":"2026101920015609700_jjag154-B19","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.immuni.2016.03.009","article-title":"Enteric viruses ameliorate gut inflammation via toll-like receptor 3 and toll-like receptor 7-mediated interferon-\u03b2 production","volume":"44","author":"Yang","year":"2016","journal-title":"Immunity"},{"key":"2026101920015609700_jjag154-B20","doi-asserted-by":"publisher","first-page":"999","DOI":"10.3748\/wjg.v23.i6.999","article-title":"Effect of toll-like receptor 3 agonist poly I: C on intestinal mucosa and epithelial barrier function in mouse models of acute colitis","volume":"23","author":"Zhao","year":"2017","journal-title":"World J Gastroenterol"},{"key":"2026101920015609700_jjag154-B21","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.4049\/jimmunol.171.6.3154","article-title":"Subcellular localization of Toll-like receptor 3 in human dendritic cells","volume":"171","author":"Matsumoto","year":"2003","journal-title":"J Immunol"},{"key":"2026101920015609700_jjag154-B22","first-page":"929","article-title":"Dual topology of functional Toll-like receptor 3 expression in human hepatocellular carcinoma: differential signaling mechanisms of TLR3-induced NF-kappaB activation and apoptosis","volume":"33","author":"Yoneda","year":"2008","journal-title":"Int J Oncol"},{"key":"2026101920015609700_jjag154-B23","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s00262-021-03109-w","article-title":"Blood DCs activated with R848 and poly(I: C) induce antigen-specific immune responses against viral and tumor-associated antigens","volume":"71","author":"H\u00e4nel","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"2026101920015609700_jjag154-B24","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41586-020-2424-4","article-title":"Structural cells are key regulators of organ-specific immune responses","volume":"583","author":"Krausgruber","year":"2020","journal-title":"Nature"},{"key":"2026101920015609700_jjag154-B25","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1093\/ibd\/izac240","article-title":"How to minimize placebo response and remission rates","volume":"29","author":"Ainsworth","year":"2023","journal-title":"Inflamm Bowel Dis"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/10\/jjag154\/72116570\/jjag154.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/10\/jjag154\/72116570\/jjag154.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:02:05Z","timestamp":1792454525000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjag154\/8943759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,9]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjag154","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,10]]},"article-number":"jjag154"}}